Prostate Cancer - Results from #1400

A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. February 16, 2024

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong S February 16, 2024

eHealth literacy in prostate cancer: A systematic review. February 16, 2024

The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance. February 16, 2024

Novel hormonal therapy versus standard of care-A registry-based comparative effectiveness evaluation for mCRPC-patients. February 16, 2024

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy. February 16, 2024

Initial COBRA Results: Clarity’s SAR-bisPSMA Is Safe and Highly Effective in Detecting Tumours in Prostate Cancer Patients. Phase 3 Planning Underway. February 15, 2024

ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature. February 15, 2024

Understanding Spatial Correlation Between Multiparametric MRI Performance and Prostate Cancer. February 15, 2024

Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care. February 15, 2024

Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. February 15, 2024

Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis. February 15, 2024

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer. February 15, 2024

The yin and yang of chromosomal instability in prostate cancer. February 14, 2024

Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer. February 14, 2024

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab. February 14, 2024

Plant-based diet associated with better quality of life in prostate cancer survivors. February 14, 2024

The impact of prognostic group classification on prostate cancer progression in intermediate-risk patients according to the European Association of Urology system: results in 479 patients treated with robot-assisted radical prostatectomy at a single terti February 14, 2024

Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate Cancer. February 14, 2024

Use of Persuasive Language in Communication of Risk during Prostate Cancer Treatment Consultations. February 14, 2024

Page 71 of 1438